Apollomics, Inc. (APLM) AI Stock Analysis
APLM AI stock analysis summary
AI ResearchApollomics, Inc. (APLM) is a clinical-stage biopharmaceutical company developing targeted molecular therapies and immuno-oncology treatments. For FY2025, revenue increased 4192.9% to $8.5M while net losses narrowed to -$10.9M. As of March 31, 2026, the company held $3.3M in cash and short-term investments against -$3.2M in shareholders' equity.
- Market cap
- $61.5M
- Revenue (TTM)
- $8.8M
- P/E
- —
- 1Y return
- -34.0% S&P 500 16.8%
- Avg. target
- $2.00 -90.5% vs last close
Bull case
- FY2025 revenue surged 4192.9% year-over-year to $8.5M, driving a 5-year revenue CAGR of 35.8% from FY2020.
- Annual net losses improved significantly from -$53.9M in FY2024 to -$10.9M in FY2025.
- The stock has gained 12.9% year-to-date and trades 11.5% above its 200-day average.
Bear case
- Wall Street analysts maintain a mean price target of $2.00, indicating a 90.5% downside from the last close of $21.10.
- The company produced -$10.4M in free cash flow during FY2025 and held only $3.3M in cash and short-term investments as of March 31, 2026.
- Shareholders' equity stood at -$3.2M with a current ratio of 0.96 as of March 31, 2026.
What Apollomics does
Apollomics, Inc. is a Foster City, California-based clinical-stage biopharmaceutical firm established in 2015. The company develops oncology therapies that target molecular pathways and harness the immune system. Its clinical pipeline features Vebreltinib (APL-101), an oral c-Met inhibitor in Phase 2 trials for non-small cell lung cancer, and uproleselan (APL-106) in Phase 3 clinical trials for acute myeloid leukemia. Other candidates include APL-102 in Phase 1 trials, APL-122 in Phase 1 dose escalation trials for brain cancers, and completed Phase 1 candidate APL-108. Apollomics is also developing preclinical immuno-oncology candidates, including APL-501, APL-502, APL-801, and APL-810.
Growth and profitability
Revenue has fluctuated heavily, moving from $2,000 in FY2021 to $323,000 in FY2022, $821,000 in FY2023, and $198,000 in FY2024. In FY2025, revenue jumped 4192.9% to $8.5M, supported by a 5-year revenue CAGR of 35.8% from FY2020 to FY2025. Gross margin stood at 97.0% in FY2025, while operating margin was -111.4%. Net losses narrowed from -$240.8M in FY2022 and -$53.9M in FY2024 to -$10.9M in FY2025. For the trailing twelve months ended March 31, 2026, revenue totaled $8.8M, with quarterly revenue growth of 380.8% year-over-year and an eps_ttm of -$7.57.
Balance sheet and cash flow
As of March 31, 2026, Apollomics had $3.3M in cash and short-term investments and $643,000 in total debt, yielding net cash of $2.6M. Shareholders' equity was -$3.2M and total assets were $6.7M, alongside a current ratio of 0.96. Operating cash flow was -$10.4M in FY2025, matching free cash flow of -$10.4M. Research and development expenses were $5.5M for FY2025. Over 5 years, the company's share count increased 213.5%.
Valuation and performance
Apollomics trades at a price-to-sales multiple of 7.0x and an enterprise value-to-revenue multiple of 7.7x, based on a market cap of $61.5M and an enterprise value of $65.6M. Its price-to-sales multiple is higher than the 4.1x median of its US-listed Healthcare peers. Its price-to-book ratio is 8.1x. Over the past year, the stock fell 34.0%, trailing the S&P 500 return of 16.8%. However, the stock is up 12.9% year-to-date and sits 11.5% above its 200-day average.
What analysts expect
Apollomics carries a mean price target of $2.00, which sits 90.5% below its last close of $21.10 on October 16, 2026. The company recorded 0 EPS beats over the last 4 quarters. Meanwhile, insider ownership stands at 56.5%, institutional ownership is 0.4%, and short interest represents 0.3% of the float.
Key risks and what to watch
- Apollomics faces liquidity pressure with $3.3M in cash and short-term investments after burning -$10.4M in operating cash flow during FY2025.
- Shareholders face ongoing dilution risk after the company expanded its share count by 213.5% over 5 years.
- The equity exhibits elevated volatility with a beta of 1.54 and fell 34.0% over the past year.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this APLM AI stock analysis
This page is an AI-written research summary of Apollomics, Inc. (APLM). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: APLM income statement, APLM balance sheet, APLM key metrics, APLM chart. See the APLM stock overview for the latest quote and news.
APLM AI stock analysis FAQ
What is Apollomics' primary clinical focus?
Apollomics develops targeted cancer therapies and immuno-oncology candidates, including lead clinical assets Vebreltinib (APL-101) in Phase 2 trials and uproleselan (APL-106) in Phase 3 trials.
What were Apollomics' revenue and earnings results in FY2025?
Revenue expanded 4192.9% to $8.5M in FY2025, while the annual net loss narrowed to -$10.9M compared to -$53.9M in FY2024.
What is the condition of Apollomics' balance sheet?
As of March 31, 2026, Apollomics had $3.3M in cash and short-term investments, $643,000 in total debt, negative shareholders' equity of -$3.2M, and a current ratio of 0.96.
What price target do analysts have on APLM stock?
Analysts have a mean price target of $2.00 for Apollomics, which is 90.5% below its closing price of $21.10 on October 16, 2026.